A review of discrete event simulation in National Coordinating Centre for Health Technology Assessment-funded work and a case study exploring the cost-effectiveness of testing for thrombophilia in patients presenting with an initial idiopathic venous thromboembolism

A review of modelling work funded by the National Coordinating Centre for Health Technology Assessment (NCCHTA) was undertaken to quantify the use of discrete event simulation (DES) techniques in health economics. A case study, funded by the NCCHTA, estimating the cost-effectiveness of thrombophilia testing is presented. Thrombophilia may increase the risk of venous thromboembolism (VTE) which can be fatal; however, the preventative treatment, warfarin, is associated with an increased risk of haemorrhage, which is also potentially fatal. A DES model, populated from literature reviews and incorporating VTE events, haemorrhages and death was constructed. The most cost-effective duration of warfarin treatment (‘standard treatment’ of 3 or 6 months, 10 years, 20 years or lifelong) was estimated for patients with initial idiopathic VTE, sub-divided into age, gender, VTE type and known thrombophilia type groups. The primary goal was to ascertain, for each sub-group, whether the cost of thrombophilia testing for all patients, given subsequent tailoring of warfarin duration, would be cost-effective. Thrombophilia testing was estimated to be cost-effective in most sub-groups; however these results are subject to large uncertainty. Primary research is required before a definitive conclusion can be reached.

[1]  P. Roderick,et al.  The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model. , 2003, Health Technology Assessment.

[2]  A A Stinnett,et al.  Net Health Benefits , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[3]  C. Shaw,et al.  Systematic review of respite care in the frail elderly. , 2009, Health technology assessment.

[4]  M Gent,et al.  A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. , 1999, The New England journal of medicine.

[5]  P. Reitsma,et al.  Genetic risk factors for venous thrombosis. , 2000, Molecular genetics and metabolism.

[6]  J. Karnon,et al.  The clinical effectiveness and cost-effectiveness of screening programmes for amblyopia and strabismus in children up to the age of 4-5 years: a systematic review and economic evaluation. , 2008, Health technology assessment.

[7]  Mark Stevenson,et al.  Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis. , 2006, Health technology assessment.

[8]  James Douketis,et al.  Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism , 2003, Annals of Internal Medicine.

[9]  M. Morgan,et al.  The clinical course of deep vein thrombosis in patients with gynecologic cancer. , 2002, Gynecologic oncology.

[10]  G. Hankey,et al.  Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. , 2006, Archives of internal medicine.

[11]  P. Royle,et al.  Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice. , 2002, Health technology assessment.

[12]  P Barton,et al.  The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. , 2004, Health technology assessment.

[13]  B. Wiman,et al.  The Risk of Recurrent Venous Thromboembolism in Carriers and Non-carriers of the G1691A Allele in the Coagulation Factor V Gene and the G20210A Allele in the Prothrombin Gene , 1999, Thrombosis and Haemostasis.

[14]  P. Royle,et al.  The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review. , 2002, Health technology assessment.

[15]  N. Waugh,et al.  Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. , 2004, Health technology assessment.

[16]  M. Sculpher,et al.  Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. , 2005, Health economics.

[17]  A J Sutton,et al.  How should we diagnose suspected deep-vein thrombosis? , 2006, QJM : monthly journal of the Association of Physicians.

[18]  L. Curtis,et al.  Unit Costs of Health and Social Care 2016 , 2015 .

[19]  P. Oakes,et al.  Unit Costs of Health and Social Care 2006 , 2006 .

[20]  B. Gage,et al.  The Effect of Stroke and Stroke Prophylaxis With Aspirin or Warfarin on Quality of Life , 1996 .

[21]  Paolo Prandoni,et al.  The Long-Term Clinical Course of Acute Deep Venous Thrombosis , 1996, Annals of Internal Medicine.

[22]  M. Dennis,et al.  A systematic review of the effectiveness, cost-effectiveness and barriers to implementation of thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHS. , 2002, Health technology assessment.

[23]  P. Prandoni,et al.  The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. , 1997, Haematologica.

[24]  M. Drummond,et al.  A systematic review of the effectiveness and cost-effectiveness of different models of community-based respite care for frail older people and their carers. , 2007, Health technology assessment.

[25]  Grazyna Adamiak,et al.  Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .

[26]  J. Sterne,et al.  Epidemiological, social, diagnostic and economic evaluation of population screening for genital chlamydial infection. , 2007, Health technology assessment.

[27]  E Goyder,et al.  A review and critique of modelling in prioritising and designing screening programmes. , 2007, Health technology assessment.

[28]  M Greaves,et al.  Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. , 2006, Health technology assessment.

[29]  R Garside,et al.  The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation. , 2005, Health technology assessment.

[30]  M. Weinstein,et al.  Foundations of cost-effectiveness analysis for health and medical practices. , 1977, The New England journal of medicine.

[31]  Mark Stevenson,et al.  Thrombophilia testing in people with venous thromboembolism: systematic review and cost-effectiveness analysis. , 2009, Health technology assessment.

[32]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[33]  P Barton,et al.  Cervical screening programmes: can automation help? Evidence from systematic reviews, an economic analysis and a simulation modelling exercise applied to the UK. , 2005, Health technology assessment.

[34]  J. O'Meara,et al.  A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis. , 1994, The New England journal of medicine.

[35]  B. Delaney,et al.  Systematic review and modelling of the investigation of acute and chronic chest pain presenting in primary care. , 2004, Health technology assessment.

[36]  M. Pitt,et al.  The effectiveness and cost-effectiveness of dual-chamber pacemakers compared with single-chamber pacemakers for bradycardia due to atrioventricular block or sick sinus syndrome: systematic review and economic evaluation. , 2005, Health technology assessment.

[37]  H. Boccalon,et al.  Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study. , 2000, Archives of internal medicine.

[38]  K. Stein,et al.  The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model. , 2007, Health technology assessment.

[39]  Paul Kind,et al.  Variations in population health status: results from a United Kingdom national questionnaire survey , 1998, BMJ.

[40]  M. Sculpher,et al.  Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.

[41]  E Berry,et al.  Intravascular ultrasound-guided interventions in coronary artery disease: a systematic literature review, with decision-analytic modelling, of outcomes and cost-effectiveness. , 2000, Health technology assessment.

[42]  J Raftery,et al.  A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. , 2005, Health technology assessment.

[43]  J Raftery,et al.  Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. , 2005, Health technology assessment.

[44]  L. Cristina,et al.  High plasma levels of factor VIII and risk of recurrence of venous thromboembolism , 2004, British journal of haematology.

[45]  M. Prins,et al.  Long-Term Treatment of Venous Thromboembolic Disease , 1999, Thrombosis and Haemostasis.

[46]  M. Sculpher,et al.  Etanercept and efalizumab for the treatment of psoriasis: a systematic review. , 2006, Health technology assessment.

[47]  British Medical Assocation.  The british national formulary , 1965 .

[48]  M Sculpher,et al.  Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. , 2006, Health technology assessment.

[49]  Frits R Rosendaal,et al.  Thrombophilia, clinical factors, and recurrent venous thrombotic events. , 2005, JAMA.

[50]  G Leone,et al.  The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. , 1999, The New England journal of medicine.

[51]  J. Douketis,et al.  Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. , 1998, JAMA.